Phase II Pilot Study of 2nd Line Gemcitabine and Nivolumab for Advanced SCLC
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2018
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 30 Nov 2018 Status changed from not yet recruiting to recruiting.
- 28 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 1 Nov 2018.
- 14 Sep 2018 New trial record